| 1: AJNR
Am J Neuroradiol. 2006 Aug;27(7):1559-61. |
|
-
Epidermal nevus syndrome with internal carotid artery
occlusion and intracranial and orbital lipomas.
Canyigit
M, Oguz
KK.
Department of Radiology, Hacettepe University Faculty of Medicine, 06100
Sihhiye, Ankara, Turkey.
We report a case of epidermal nevus syndrome involving the brain in which
there is chronic occlusion of the left distal internal carotid artery
resulting in ipsilateral atrophy. Orbital and cerebellopontine angle cistern
lipomas and a wide cortical developmental malformation are associated with
the condition. We present MR imaging findings of a patient and discuss
features in the context of other neurocutaneous diseases.
Publication Types:
PMID: 16908580 [PubMed - indexed for MEDLINE]
-
| 2: AJNR
Am J Neuroradiol. 2006 Aug;27(7):1483-5. |
|
-
CNS metastases of carcinoma ex pleomorphic adenoma of the
parotid gland.
Sheedy
SP, Welker
KM, DeLone
DR, Gilbertson
JR.
Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN
55905, USA. sheedy.shannon@mayo.edu
Pleomorphic adenomas (PAs), also known as benign mixed tumors, are common
tumors of the parotid gland. These tumors occasionally undergo malignant
transformation, with potentially devastating consequences. This case report
presents the clinical and radiographic features of a rare case of biopsy
proved brain and spinal cord metastases arising from carcinoma ex PA of the
parotid gland.
Publication Types:
PMID: 16908563 [PubMed - indexed for MEDLINE]
-
| 3: AJNR
Am J Neuroradiol. 2006 Aug;27(7):1450-3. |
|
-
Differential cortical thickness across the central sulcus:
a method for identifying the central sulcus in the presence of mass effect
and vasogenic edema.
Biega
TJ, Lonser
RR, Butman
JA.
Department of Neuroradiology, George Washington University Medical Center,
Washington, DC, USA.
BACKGROUND AND PURPOSE: Identification of the motor strip on MR imaging
studies is difficult in the presence of mass effect and vasogenic edema
because sulcal landmarks are obscured. We hypothesize that a difference in
cortical thickness between the motor and sensory strips is readily apparent
on T2-weighted images in the presence of vasogenic edema and reliably
identifies the central sulcus. METHODS: Thirteen patients with brain tumors
resulting in vasogenic edema near the central sulcus were identified. The
cortical thickness of the anterior and posterior banks of the central sulcus
as well as the neighboring sulci in the frontal and parietal lobes were
measured from T2-weighted images. Similar measures were obtained from
neighboring sulci in the frontal and parietal lobes. Location of the central
sulcus was confirmed with standard anatomic landmarks in all patients and by
intraoperative cortical mapping in 2 patients. RESULTS: A twofold difference
in cortical thickness between the anterior and posterior banks of the
central sulcus uniquely identified the central sulcus on T2-weighted images
in the presence of vasogenic edema, despite the marked distortion of sulcal
anatomy as a result of mass effect. This relationship was not present in
neighboring sulci. CONCLUSION: Cytoarchitectonic differences in the motor
and sensory cortices result in a markedly thicker posterior than anterior
bank of the central sulcus that is readily visible on routine T2-weighted
images in the presence of vasogenic edema. Therefore, the cortical thickness
can serve as a complementary method in identification of the motor strip in
patients with mass effect.
PMID: 16908556 [PubMed - indexed for MEDLINE]
-
| 4: AJNR
Am J Neuroradiol. 2006 Aug;27(7):1441-6. |
|
-
Trading spectral separation at 3T for acquisition speed
in multi spin-echo spectroscopic imaging.
Dydak
U, Meier
D, Lamerichs
R, Boesiger
P.
Institute of Biomedical Engineering, University of Zurich and Swiss Federal
Institute of Technology Zurich, Gloriastrasse 35, CH-8092 Zurich,
Switzerland. ulrike.dydak@ethz.ch
Fast multiple spin-echo spectroscopic imaging, also called turbo
spectroscopic imaging (TSI), may be enhanced in terms of acquisition speed
by taking advantage of the higher spectral separation afforded at higher
field strength and by further combining it with sensitivity encoding
(SENSE). This article demonstrates the possibilities of this approach at 3T,
resulting in scan-time reductions of up to a factor of 10. High-resolution,
in vivo, single- and multiple-section spectroscopic imaging data are
presented.
PMID: 16908554 [PubMed - indexed for MEDLINE]
-
| 5: Cancer. 2006 Oct
3; [Epub ahead of print] |
|
-
Phase II study of oxaliplatin in children with recurrent
or refractory medulloblastoma, supratentorial primitive neuroectodermal
tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor
consortium study.
Fouladi
M, Blaney
SM, Poussaint
TY, Freeman
BB 3rd, McLendon
R, Fuller
C, Adesina
AM, Hancock
ML, Danks
MK, Stewart
C, Boyett
JM, Gajjar
A.
St. Jude Children's Research Hospital, Memphis, Tennessee.
BACKGROUND.: An open-label Phase II study of oxaliplatin was conducted to
evaluate its safety and efficacy in children with recurrent or refractory
medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET),
and atypical teratoid rhabdoid tumor (ATRT). METHODS.: Patients were
stratified as follows: stratum IA, first recurrence MB with measurable
disease; IB, recurrent MB with only cerebral spinal fluid (CSF) positivity
or linear leptomeningeal disease (LLD); IC, MB >/=second recurrence;
stratum II, recurrent SPNET; stratum III, recurrent ATRT. Patients received
oxaliplatin, 130 mg/m(2) intravenously over 2 hours every 3 weeks. The
primary objective was to estimate the sustained response rate in stratum 1A.
Plasma ultrafiltrate platinum pharmacokinetics were evaluated. RESULTS.: A
total of 43 patients with a median age of 8.5 years (range, 0.6-18.9 years)
were enrolled. In stratum 1A, 2 of 15 had partial responses (PRs, 1
sustained PR). No responses were observed in other strata. The most frequent
Grade 3 and 4 toxicities included thrombocytopenia (25.6%), neutropenia
(16.3%), leukopenia (12%), increase in serum alanine transaminase (ALT)
(7%), vomiting (4.7%), and sensory neuropathy (4.7%). No severe ototoxicity
or nephrotoxicity was reported. Plasma ultrafiltrate platinum
pharmacokinetic parameters were similar to adults, with a median clearance
of 12.2 L/hr (range, 4.4-30 L/hr) and median area under the curve
(AUC(0-infinity)) of 9.4 mug/mL/hr (range, 6.2-13.9 mug/mL/hr).
CONCLUSIONS.: Oxaliplatin was well tolerated in children but has limited
activity in children with recurrent CNS embryonal tumors previously treated
with platinum compounds. Cancer 2006. (c) 2006 American Cancer Society.
PMID: 17019740 [PubMed - as supplied by publisher]
-
| 6: Cancer Res. 2006 Oct
1;66(19):9535-42. |
|
-
Increased Fibroblast Growth Factor-Inducible 14
Expression Levels Promote Glioma Cell Invasion via Rac1 and Nuclear Factor-{kappa}B
and Correlate with Poor Patient Outcome.
Tran
NL, McDonough
WS, Savitch
BA, Fortin
SP, Winkles
JA, Symons
M, Nakada
M, Cunliffe
HE, Hostetter
G, Hoelzinger
DB, Rennert
JL, Michaelson
JS, Burkly
LC, Lipinski
CA, Loftus
JC, Mariani
L, Berens
ME.
Cancer and Cell Biology Division, Translational Genomics Research Institute,
Phoenix, Arizona.
Glial tumors progress to malignant grades by heightened proliferation and
relentless dispersion throughout the central nervous system. Understanding
genetic and biochemical processes that foster these behaviors is likely to
reveal specific and effective targets for therapeutic intervention. Our
current report shows that the fibroblast growth factor-inducible 14 (Fn14),
a member of the tumor necrosis factor (TNF) receptor superfamily, is
expressed at high levels in migrating glioma cells in vitro and invading
glioma cells in vivo. Forced Fn14 overexpression stimulates glioma cell
migration and invasion, and depletion of Rac1 by small interfering RNA
inhibits this cellular response. Activation of Fn14 signaling by the ligand
TNF-like weak inducer of apoptosis (TWEAK) stimulates migration and
up-regulates expression of Fn14; this TWEAK effect requires Rac1 and nuclear
factor-kappaB (NF-kappaB) activity. The Fn14 promoter region contains NF-kappaB
binding sites, which mediate positive feedback causing sustained
overexpression of Fn14 and enduring glioma cell invasion. Furthermore, Fn14
gene expression levels increase with glioma grade and inversely correlate
with patient survival. These results show that the Fn14 cascade operates as
a positive feedback mechanism for elevated and sustained Fn14 expression.
Such a feedback loop argues for aggressive targeting of the Fn14 axis as a
unique and specific driver of glioma malignant behavior. (Cancer Res 2006;
66(19): 9535-42).
PMID: 17018610 [PubMed - in process]
-
| 7: Cancer Res. 2006 Oct
1;66(19):9428-36. |
|
-
High-resolution Global Genomic Survey of 178 Gliomas
Reveals Novel Regions of Copy Number Alteration and Allelic Imbalances.
Kotliarov
Y, Steed
ME, Christopher
N, Walling
J, Su
Q, Center
A, Heiss
J, Rosenblum
M, Mikkelsen
T, Zenklusen
JC, Fine
HA.
Neuro-Oncology Branch, National Cancer Institute.
Primary brain tumors are the fourth leading cause of cancer mortality in
adults under the age of 54 years and the leading cause of cancer mortality
in children in the United States. Therapy for the most common type of
primary brain tumors, gliomas, remains suboptimal. The development of new
and more effective treatments will likely require a better understanding of
the biology of these tumors. Here, we show that use of the high-density 100K
single-nucleotide polymorphism arrays in a large number of primary tumor
samples allows for a much higher resolution survey of the glioma genome than
has been previously reported in any tumor type. We not only confirmed
alterations in genomic areas previously reported to be affected in gliomas,
but we also refined the location of those sites and uncovered multiple,
previously unknown regions that are affected by copy number alterations
(amplifications, homozygous and heterozygous deletions) as well as allelic
imbalances (loss of heterozygosity/gene conversions). The wealth of genomic
data produced may allow for the development of a more rational molecular
classification of gliomas and serve as an important starting point in the
search for new molecular therapeutic targets. (Cancer Res 2006; 66(19):
9428-36).
PMID: 17018597 [PubMed - in process]
-
| 8: Childs
Nerv Syst. 2006 Aug 29; [Epub ahead of print] |
|
-
Fatal glioblastoma multiforme in a patient with
neurofibromatosis type I: the dilemma of systematic medical follow-up.
Distelmaier
F, Fahsold
R, Reifenberger
G, Messing-Juenger
M, Schaper
J, Schneider
DT, Gobel
U, Mayatepek
E, Rosenbaum
T.
Department of General Pediatrics, University Children's Hospital, Heinrich-Heine-University
Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany, distelmaier@med.uni-duesseldorf.de.
INTRODUCTION: Neurofibromatosis type I (NF1) is one of the most prevalent
genetic diseases of the nervous system. Although the majority of NF1
patients are only mildly affected, the risk of developing malignancies is
significantly increased in this population. CASE REPORT: Here, we present a
9-year-old girl with clinical stigmata of NF1 and a rapidly evolving
glioblastoma multiforme. Molecular genetic analysis uncovered a novel
missense mutation in Exon 32 of the NF1 gene [c.6032C>A(p.Ala2011Glu)].
DISCUSSION: The girl's death 3 days after diagnosis of the brain tumor
exemplifies that NF1 still is a life-threatening disease despite its
generally benign course in most patients. However, it remains questionable
if a fatal course as reported here can be prevented by routine MRI
screening.
PMID: 17009007 [PubMed - as supplied by publisher]
-
| 9: Clin Neuropathol.
2006 Sep-Oct;25(5):227-31. |
|
Morphophenotype of medulloblastoma in children and
adults. The size of nuclei.
Dagostino
C, Clara
E, Chio
A, Giordana
MT.
Department of Neuroscience, University of Torino, Italy.
OBJECTIVE: Uniform cells with round, regular nuclei characterize the typical
histologic aspect of medulloblastoma. Enlargement of nuclei distinguishes
the large-cell medulloblastoma variant and is associated with a poor
prognosis in pediatric medulloblastomas. The aim of the present study was to
compare the size of nuclei between pediatric and adult medulloblastomas by a
morphometric analysis. MATERIAL AND METHODS: In 79 neurosurgical specimens
of cerebellar medulloblastomas, the maximum nuclear diameter of the largest
nuclei was measured. Measurements were performed with a digital-image
analysis system. The measure of the maximum diameter was chosen in order to
reduce the split cell error. RESULTS: The difference between the mean values
in children and adults was statistically significant (p = 0,001). The
distribution of maximum values measured in each case had two distinct peaks
in the two age groups, in 3.5% of adult cases and in more than 30% of
pediatric cases the maximum nuclear size was superior to 12 microm.
CONCLUSIONS: The present results show that nuclei of tumor cells in
pediatric medulloblastomas are larger than those in adult medulloblastomas
and confirm that the phenotype of medulloblastoma is different in the two
age groups. Distinct genetic events can, thus, underlie medulloblastoma in
childhood and adult age, the prognostic role of genetic variables can differ
by age.
PMID: 17007445 [PubMed - in process]
-
| 10: Int
J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):810-7. |
|
-
RPA classification has prognostic significance for
surgically resected single brain metastasis.
Tendulkar
RD, Liu
SW, Barnett
GH, Vogelbaum
MA, Toms
SA, Jin
T, Suh
JH.
Department of Radiation Oncology, Brain Tumor Institute, Cleveland Clinic,
Cleveland, OH.
Purpose: To retrospectively evaluate prognostic factors that correlate with
overall survival among patients with a surgically resected single brain
metastasis. Methods and Materials: An Institutional Review Board-approved
database of the Cleveland Clinic Brain Tumor Institute was queried for
patients with a single brain metastasis treated by surgical resection
between February 1984 and January 2004. The primary endpoint was overall
survival from the date of surgery by the Kaplan-Meier method. Results: A
total of 271 patients were included. Statistically significant variables for
improved survival on multivariate analysis included age <65 years, lack
of extracranial metastases, control of primary tumor, histology
(non-small-cell lung carcinoma), and use of stereotactic radiosurgery. The
median survival for all patients was 10.2 months. Survival of patients in
recursive partitioning analysis (RPA) class 1 was better (21.4 months) than
those in RPA class 2 (9.0 months, p < 0.001), RPA class 3 (8.9 months, p
= 0.15), or the combined group of RPA classes 2 and 3 (9.0 months, p <
0.001). Patients had a median survival of 10.6 months after documented gross
total resection and 8.7 months after subtotal resection, which approached
statistical significance (p = 0.07). Those who were treated with
stereotactic radiosurgery had a median survival of 17.1 months, which was
greater than patients who were not treated with stereotactic radiosurgery
(8.9 months, p = 0.006). Conclusions: This analysis supports the prognostic
significance of the RPA classification in patients with a single brain
metastasis who undergo surgical resection and adjuvant therapy. RPA class 1
patients have a very favorable prognosis with a median survival of 21.4
months.
PMID: 17011454 [PubMed - in process]
-
| 11: J Neurooncol.
2006 Oct 4; [Epub ahead of print] |
|
-
A pilot study of primary temozolomide chemotherapy and
deferred radiotherapy in elderly patients with glioblastoma.
Chamberlain
MC, Chalmers
L.
Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research
Institute, 12902 Magnolia Avenue, Tampa, FL, 33612-0804, USA, ChambeMC@moffitt.usf.edu.
There is no standard of care for elderly patients (age >/= 70 years) with
newly diagnosed glioblastoma (GBM). In 15 consecutive patients (median age
79 years) treated with temozolomide (TMZ) (42 days on; 14 days off), median
survival was 6 months (range 4-14 months). This pilot study suggests that
low dose daily TMZ may represent an alternative and equally effective
treatment to more traditionally administered radiotherapy.
PMID: 17019532 [PubMed - as supplied by publisher]
-
| 12: J Neurooncol.
2006 Sep 29; [Epub ahead of print] |
|
-
Gefitinib concentrations in human glioblastoma tissue.
Hofer
S, Frei
K.
Medical Oncology, University Hospital Zurich, Ramistrasse 100, 8091, Zurich,
Switzerland, silvia.hofer@usz.ch.
PMID: 17008949 [PubMed - as supplied by publisher]
-
| 13: J
Nucl Med. 2006 Oct;47(10):1612-21. |
|
-
Kinetic Analysis of 3'-Deoxy-3'-18F-Fluorothymidine in
Patients with Gliomas.
Muzi
M, Spence
AM, O'sullivan
F, Mankoff
DA, Wells
JM, Grierson
JR, Link
JM, Krohn
KA.
Department of Radiology, University of Washington, Seattle, Washington;
2Department of Neurology, University of Washington, Seattle, Washington; and
3Department of Statistics, University College Cork, Cork, Ireland.
3'-Deoxy-3'-fluorothymidine (FLT), a thymidine analog, is under
investigation for monitoring cellular proliferation in gliomas, a potential
measure of disease progression and response to therapy. Uptake may result
from retention in the biosynthetic pathway or leakage via the disrupted
blood-tumor barrier. Visual analysis or static measures of (18)F-FLT uptake
are problematic as transport and retention cannot be distinguished. METHODS:
Twelve patients with primary brain tumors were imaged for 90 min of dynamic
(18)F-FLT PET with arterial blood sampling. Total blood activity was
corrected for labeled metabolites to provide an FLT input function. A
2-tissue compartment, 4-rate-constant model was used to determine
blood-to-tissue transport (K(1)) and metabolic flux (K(FLT)). Modeling
results were compared with MR images of blood-brain barrier (BBB) breakdown
revealed by gadolinium (Gd) contrast enhancement. Parametric image maps of
K(1) and K(FLT) were produced by a mixture analysis approach. RESULTS:
Similar to prior work with (11)C-thymidine, identifiability analysis showed
that K(1) (transport) and K(FLT) (flux) could be estimated independently for
sufficiently high K(1) values. However, estimation of K(FLT) was less robust
at low K(1) values, particularly those close to normal brain. K(1) was
higher for MRI contrast-enhancing (CE) tumors (0.053 +/- 0.029 mL/g/min)
than noncontrast-enhancing (NCE) tumors (0.005 +/- 0.002 mL/g/min; P <
0.02), and K(FLT) was higher for high-grade tumors (0.018 +/- 0.008 mL/g/min,
n = 9) than low-grade tumors (0.003 +/- 0.003 mL/g/min, n = 3; P < 0.01).
The flux in NCE tumors was indistinguishable from contralateral normal brain
(0.002 +/- 0.001 mL/g/min). For CE tumors, K(1) was higher than K(FLT).
Parametric images matched region-of-interest estimates of transport and
flux. However, no patient has (18)F-FLT uptake outside of the volume of
increased permeability defined by MRI T1+Gd enhancement. CONCLUSION:
Modeling analysis of (18)F-FLT PET data yielded robust estimates of K(1) and
K(FLT) for enhancing tumors with sufficiently high K(1) and provides a
clearer understanding of the relationship between transport and retention of
(18)F-FLT in gliomas. In tumors that show breakdown of the BBB, transport
dominates (18)F-FLT uptake. Transport across the BBB and modest rates of
(18)F-FLT phosphorylation appear to limit the assessment of cellular
proliferation using (18)F-FLT to highly proliferative tumors with
significant BBB breakdown.
PMID: 17015896 [PubMed - in process]
-
| 14: J
Nucl Med. 2006 Oct;47(10):1599-606. |
|
-
Effects of Therapy with [177Lu-DOTA0, Tyr3]Octreotate in
Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and
Melanoma.
van
Essen M, Krenning
EP, Kooij
PP, Bakker
WH, Feelders
RA, de
Herder WW, Wolbers
JG, Kwekkeboom
DJ.
Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The
Netherlands; 2Department of Internal Medicine, Erasmus Medical Center,
Rotterdam, The Netherlands; and 3Department of Neurosurgery, Erasmus Medical
Center, Rotterdam, The Netherlands.
Therapy using the radiolabeled somatostatin analog
[(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) (DOTA is
1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) has been used
primarily in gastroenteropancreatic neuroendocrine tumors. Here we present
the effects of this therapy in a small number of patients with metastasized
or inoperable paragangliomas, meningiomas, small cell lung carcinomas (SCLCs),
and melanomas. METHODS: Twelve patients with paraganglioma, 5 with
meningioma, 3 with SCLC, and 2 with eye melanoma were treated. Three
meningiomas were very large and exophytic and all standard treatments had
failed. Patients with melanoma had rapidly progressive disease (PD). The
intended cumulative dose of (177)Lu-octreotate was 22.2-29.6 GBq. Effects of
the treatment on tumor size were evaluated using the Southwest Oncology
Group criteria. RESULTS: Two of 4 patients with progressive paraganglioma
had tumor regression and 1 had stable disease (SD). Of 5 patients with
stable paraganglioma, 2 had SD, 2 had PD, and in 1 patient treatment outcome
could not be determined. Paraganglioma was stable in 3 patients in whom the
disease status at the beginning of therapy was unknown. One of 4 patients
with progressive meningioma had SD and 3 patients had PD. One patient with
stable meningioma at the beginning of therapy had SD. All patients with SCLC
or melanoma died within 5 mo after starting therapy because of tumor
progression. Although not statistically significant, a positive trend was
found between high uptake on pretherapy somatostatin receptor scintigraphy
and treatment outcome. CONCLUSION: (177)Lu-Octreotate can be effective in
patients with paraganglioma and meningioma. Response rates are lower than
those in patients with gastroenteropancreatic neuroendocrine tumors. Most
meningiomas were very large. Further studies are needed to confirm the
treatment outcome because of the limited number of patients.
(177)Lu-Octreotate did not have antitumor effects in patients with small
lung carcinoma and melanoma.
PMID: 17015894 [PubMed - in process]
-
| 15: Neuroradiology. 2006
Sep 30; [Epub ahead of print] |
|
-
Comparison of first-pass and second-bolus dynamic
susceptibility perfusion MRI in brain tumors.
Spampinato
MV, Wooten
C, Dorlon
M, Besenski
N, Rumboldt
Z.
Department of Radiology, Medical University of South Carolina, 169 Ashley
Avenue, P.O. Box 250322, Charleston, SC, 29425, USA, spampin@musc.edu.
INTRODUCTION: Our goal was to evaluate whether the T1 shortening effect
caused by contrast leakage into brain tumors, a well-known confounding
effect in the quantification of relative cerebral blood volume (rCBV)
measurements, may be corrected by the administration of a predose of
gadolinium-DTPA. METHODS: As part of their presurgical imaging protocol, 25
patients with primary brain tumors underwent two consecutive dynamic
susceptibility-weighted contrast-enhanced (DSC) perfusion MR studies.
Intratumoral rCBV measurements and normalized rCBV values obtained during
the first-pass and second-bolus studies were compared (Wilcoxon signed-ranks
test). The frequency of relatively increased rCBV ratios on the second-bolus
study was compared between enhancing and non-enhancing neoplasms (Fisher's
exact test). Postprocessing perfusion studies were evaluated for image
quality on a scale of 0-3 (Wilcoxon signed-ranks test). Four studies were
excluded due to unacceptable image quality. RESULTS: Mean normalized rCBVs
were 9.04 (SD 4.64) for the first-pass and 7.99 (SD 3.84) for the
second-bolus study. There was no statistically significant difference
between the two perfusion studies in either intratumoral rCBV (P=0.237) or
rCBV ratio (P=0.181). Five enhancing and four non-enhancing tumors showed a
relative increase in rCBV ratio on the second-bolus study, without a
significant difference between the groups. Image quality was not
significantly different between perfusion studies. CONCLUSION: Our results
did not demonstrate a significant difference between first-pass and
second-bolus rCBV measurements in DSC perfusion MR imaging. The
administration of a predose of gadolinium-DTPA does not appear to be an
efficient way of compensating for the underestimation of intratumoral rCBV
values due to the T1 shortening effect.
PMID: 17013587 [PubMed - as supplied by publisher]
-
| 16: Neurosurgery. 2006 Sep
28; [Epub ahead of print] |
|
-
VARIANT OF THE CHEK2 GENE AS A PROGNOSTIC MARKER IN
GLIOBLASTOMA MULTIFORME.
Simon
M, Ludwig
M, Fimmers
R, Mahlberg
R, Muller-Erkwoh
A, Koster
G, Schramm
J.
Department of Neurosurgery, University of Bonn, Bonn, Germany (Simon,
Muller-Erkwoh, Koster and Schramm) Institute for Clinical Biology,
University of Bonn, Bonn, Germany (Ludwig) Institute for Medical Statistics
and Information, Bonn, Germany (Fimmers).
OBJECTIVE: Germline mutations of the CHEK2 tumor suppressor gene have been
found in families with the Li-Fraumeni syndrome (LFS). Patients with LFS
experience a variety of cancers, including malignant astrocytomas. We
investigated a potential role for a CHEK2 gene polymorphism in glioblastomas.
METHODS: A genetic polymorphism of the CHEK2 gene (CHEK2 SNP rs2017309 A/T)
was genotyped in a series of glioblastoma patients (n = 213) and population
controls (n = 192). Subsets of tumors were analyzed for loss of
heterozygosity 22q(n = 66), loss of heterozygosity CHEK2 (n = 53), CHEK2
expression (n = 21), and CHEK2 coding sequence alterations (n = 18). CHEK2
SNP rs2017309 genotyping findings and traditional clinicopathological
parameters were correlated with the patients' prognoses. RESULTS: No
association between the CHEK2 SNP and glioblastoma formation was observed.
No CHEK2 coding sequence aberrations or tumors completely lacking CHEK2
protein were identified. However, the presence of the CHEK2 rs2017309 A
allele was significantly associated with an adverse prognosis (P = 0.034),
particularly among patients undergoing postoperative chemotherapy and
radiotherapy (n = 28, median survival 10.5 versus 15.5 mo, P = 0.008). We
could confirm the patients' age, Karnofsky Performance Scale score, and
postoperative radiotherapy and chemotherapy (all P < 0.0001, log-rank
test) as decisive prognostic factors. CONCLUSION: Our data suggest that a
CHEK2 gene polymorphism might correlate with the prognosis of glioblastoma
patients. These findings may point to an as yet unrecognized role for the
CHEK2 gene in glioblastomas.
PMID: 17016233 [PubMed - as supplied by publisher]
-
| 17: Oncogene. 2006 Oct 2; [Epub
ahead of print] |
|
-
Inhibition of IGF-I receptor in anchorage-independence
attenuates GSK-3beta constitutive phosphorylation and compromises growth and
survival of medulloblastoma cell lines.
Urbanska
K, Trojanek
J, Del
Valle L, Eldeen
MB, Hofmann
F, Garcia-Echeverria
C, Khalili
K, Reiss
K.
[1] 1Department of Neuroscience, Center for Neurovirology, Temple
University, Philadelphia, PA, USA [2] 2Faculty of Biotechnology, Department
of Cell Biology, Jagiellonian University, Krakow, Poland.
We have previously reported that insulin-like growth factor-I (IGF-I)
supports growth and survival of mouse and human medulloblastoma cell lines,
and that IGF-I receptor (IGF-IR) is constitutively phosphorylated in human
medulloblastoma clinical samples. Here, we demonstrate that a specific
inhibitor of insulin-like growth factor-I receptor (IGF-IR), NVP-AEW541,
attenuated growth and survival of mouse (BsB8) and human (D384, Daoy)
medulloblastoma cell lines. Cell cycle analysis demonstrated that G1 arrest
and apoptosis contributed to the action of NVP-AEW54. Interestingly, very
aggressive BsB8 cells, which derive from cerebellar tumors of transgenic
mice expressing viral oncoprotein (large T-antigen from human polyomavirus
JC) became much more sensitive to NVP-AEW541 when exposed to
anchorage-independent culture conditions. This high sensitivity to NVP-AEW54
in suspension was accompanied by the loss of GSK-3beta constitutive
phosphorylation and was independent from T-antigen-mediated cellular events
(Supplementary Materials). BsB8 cells were partially rescued from NVP-AEW541
by GSK3beta inhibitor, lithium chloride and were sensitized by GSK3beta
activator, sodium nitroprusside (SNP). Importantly, human medulloblastoma
cells, D384, which demonstrated partial resistance to NVP-AEW541 in
suspension cultures, become much more sensitive following SNP-mediated
GSK3beta dephosphorylation (activation). Our results indicate that
hypersensitivity of medulloblastoma cells in anchorage-independence is
linked to GSK-3beta activity and suggest that pharmacological intervention
against IGF-IR with simultaneous activation of GSK3beta could be highly
effective against medulloblastomas, which have intrinsic ability of
disseminating the CNS via cerebrospinal fluid.Oncogene advance online
publication, 2 October 2006; doi:10.1038/sj.onc.1210018.
PMID: 17016438 [PubMed - as supplied by publisher]
-
| 18: Rev Neurol.
2006 Mar 16-31;42(6):383-4. |
|
-
Comment on:
[The diagnosis and treatment of children with arachnoid
cysts associated to mild traumatic brain injury]
[Article in Spanish]
Lezcano-Ortiz
HJ, Peregrino-Reyes
R, Perez-Fonseca
M, Rodriguez-Morales
J, Estevez-Sanchez
PJ.
Publication Types:
PMID: 16575778 [PubMed - indexed for MEDLINE]
-
| 19: Rev Neurol.
2006 Mar 16-31;42(6):382-3. |
|
-
[Transient global amnesia during sexual intercourse]
[Article in Spanish]
Alonso-Navarro
H, Jimenez-Jimenez
FJ.
Publication Types:
PMID: 16575777 [PubMed - indexed for MEDLINE]
-
| 20: Rev Neurol.
2006 Mar 16-31;42(6):381-2. |
|
-
[Sexual headaches associated to an arachnoid cyst]
[Article in Spanish]
Santos
S, Larrode-Pellicer
P, Iniguez-Martinez
C, Perez-Lazaro
C, Claramonte
M, Alberti-Gonzalez
O, Martinez
L.
Publication Types:
PMID: 16575776 [PubMed - indexed for MEDLINE]
-
| 21: Surg Neurol.
2006 Oct;66(4):437-40. Epub 2006 Jul 21. |
|
-
Cortical seeding of a craniopharyngioma after craniotomy:
case report.
de
Macedo Bianco A, Madeira
LV, Rosemberg
S, Shibata
MK.
Department of Neurosurgery, 9 de Julho Hospital, 01409-001 Sao Paulo,
Brazil.
BACKGROUND: Cortical seeding of a craniopharyngioma has been rarely
reported. We present a case that ectopically recurred along the tract of a
previous surgical route. METHODS: A 27-year-old woman presented earlier with
a suprasellar craniopharyngioma. A left frontotemporal craniotomy was done
with subtotal resection of the tumor because it was strongly adhered to the
optic chiasm. Histopathology confirmed the diagnosis of craniopharyngioma.
Six months after, the patient presented with decreased visual acuity and
diplopia. She was reoperated through the previous craniotomy with a total
resection. One year after the second surgery, the patient presented with
seizures that were difficult to control. Magnetic resonance imaging revealed
a contrast-enhancing tumor with cystic and solid components on the left
temporal lobe cortex. The primary tumor bed was intact. The patient was
reoperated, and the temporal lobe tumor was totally removed. Histologic
studies showed an adamantinomatous craniopharyngioma. The patient was free
of neurologic abnormalities, and no new lesion was found in the magnetic
resonance imaging performed 1 year after the last surgery. CONCLUSIONS:
Although craniopharyngiomas exhibit a benign histopathologic pattern, a
total resection combined with careful inspection and irrigation of the
surgical field is the optimal treatment for preventing local and ectopic
recurrences. It is strongly recommended that the concerned patients have a
long-term clinical and neuroimaging follow-up.
PMID: 17015135 [PubMed - in process]
-
| 22: Pediatr Neurosurg.
2006;42(3):200-1. |
|
-
Posttraumatic intradiploic pseudomeningocele:
neuroimaging.
Gupta
DK, Mahapatra
AK.
Department of Neurosurgery, All India Institute of Medical Sciences, New
Delhi, India.
Publication Types:
PMID: 16636627 [PubMed - indexed for MEDLINE]
-
| 23: Pediatr Neurosurg.
2006;42(3):187-92. |
|
-
Atypical teratoid/rhabdoid tumor of the velum
interpositum presenting as a spontaneous intraventricular hemorrhage in an
infant: case report with long-term survival.
Donovan
DJ, Smith
AB, Petermann
GW.
Department of Surgery, Neurosurgery Service, Tripler Army Medical Center,
Honolulu, Hawaii 96859-5000, USA. donovand001@hawaii.rr.com
Atypical teratoid/rhabdoid tumors (ATRT) of infancy are highly malignant
neoplasms that are most common in the first 2 years of life. We present the
case of a 3-month-old girl who presented with the acute onset of generalized
seizures and was found to have a large spontaneous intraventricular
hemorrhage. The blood masked an underlying ATRT of the velum interpositum in
the midline of the lateral ventricles and roof of the third ventricle, the
first reported case in this location. Serial imaging studies and two
ventriculoscopic biopsies were required to establish the diagnosis of the
tumor in this unique location and in the midst of an evolving hematoma.
After surgical resection, the patient received adjuvant chemotherapy. At
4-year follow-up, the child is neurologically intact, meeting normal
developmental milestones, and imaging studies show no evidence of tumor.
ATRT were previously associated with an extremely poor prognosis, but more
recent evidence with complete surgical resection and adjuvant chemotherapy
shows extended survival in some cases, supporting an aggressive and
comprehensive approach to give these patients the best chance for a good
outcome. Spontaneous brain hemorrhage in a full-term infant requires a
diligent and persistent search to rule out an underlying neoplasm. Copyright
2006 S. Karger AG, Basel
Publication Types:
PMID: 16636624 [PubMed - indexed for MEDLINE]
-
| 24: Pediatr Neurosurg.
2006;42(3):171-3. |
|
-
Frontal bone agenesis in a patient of spinal dysraphism.
Nayak
PK, Mahapatra
AK.
Department of Neurosurgery, All India Institute of Medical Sciences, New
Delhi, India.
Associated cranial abnormalities with spinal dysraphism are not uncommon. We
came across an unusual case of a 1-year-old male child with spinal
dysraphism having lumbar meningomyelocele, who also had split cord
malformation (hemicord with intervening bony spur) with lipoma of one of the
hemicord and filum terminale. The patient also had communicating
hydrocephalus without Chiari malformation and also near-total frontal bone
agenesis. Single photon emission computed tomography scanning of brain
revealed normal perfusion. In the first stage of repair, the patient had
postoperative CSF leak for which ventriculo-peritoneal shunt was performed.
This constitutes a rare anomaly associated with spinal dysraphism. Copyright
2006 S. Karger AG, Basel
Publication Types:
PMID: 16636620 [PubMed - indexed for MEDLINE]
-
| 25: BMC
Cancer. 2006 Oct 3;6(1):234 [Epub ahead of print] |
|
-
Changes in liver mitochondrial plasticity induced by
brain tumor.
Pouliquen
DL, Olivier
C, Debien
E, Meflah
K, Vallette
FM, Menanteau
J.
ABSTRACT: BACKGROUND: Accumulating data suggest that liver is a major target
organ of systemic effects observed in the presence of a cancer. In this
study, we investigated the consequences of the presence of chemically
induced brain tumors in rats on biophysical parameters accounting for the
dynamics of water in liver mitochondria. Methods : Tumors of the central
nervous system were induced by intraveinous administration of
ethylnitrosourea (ENU) to pregnant females on the 19th day of gestation. The
mitochondrial crude fraction was isolated from the liver of each animal and
the dynamic parameters of total water and its macromolecule-associated
fraction (structured water, H2Ost) were calculated from Nuclear Magnetic
Resonance (NMR) measurements. Results : The presence of a malignant brain
tumor induced a loss of water structural order that implicated changes in
the physical properties of the hydration shells of liver mitochondria
macromolecules. This feature was linked to an increase in the membrane
cholesterol content, a way to limit water penetration into the bilayer and
then to reduce membrane permeability. As expected, these alterations in
mitochondrial plasticity affected ionic exchanges and led to abnormal
features of mitochondrial biogenesis and caspase activation. Conclusions :
This study enlightens the sensitivity of the structured water phase in the
liver mitochondria machinery to external conditions such as tumor
development at a distant site. The profound metabolic and functional changes
led to abnormal features of ion transport, mitochondrial biogenesis and
caspase activation.
PMID: 17018136 [PubMed - as supplied by publisher]
|
